Cancer Nanotechnology

Scope & Guideline

Advancing Cancer Research through Nanotechnology Innovation

Introduction

Welcome to your portal for understanding Cancer Nanotechnology, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1868-6958
PublisherSPRINGER WIEN
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2010 to 2024
AbbreviationCANCER NANOTECHNOL / Cancer Nanotechnol.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPrinz-Eugen-Strasse 8-10, A-1040 Vienna, AUSTRIA

Aims and Scopes

The journal "Cancer Nanotechnology" focuses on the innovative application of nanotechnology in cancer research and therapy. It aims to bridge the gap between nanotechnology and oncology, providing a platform for researchers to explore and publish their findings on nanomaterials and their therapeutic potential against various types of cancer.
  1. Nanoparticle Design and Synthesis:
    Research on the development of novel nanoparticles, including their synthesis and functionalization, to enhance drug delivery and therapeutic efficacy in cancer treatment.
  2. Targeted Drug Delivery Systems:
    Studies focusing on the use of nanoparticles for targeted delivery of chemotherapeutic agents, aiming to minimize side effects while maximizing treatment efficacy.
  3. Theranostics:
    Integration of therapeutic and diagnostic capabilities in nanoparticles to create theranostic agents that can monitor treatment response and improve personalized medicine.
  4. Mechanistic Studies:
    Investigations into the cellular and molecular mechanisms of action of nanoparticles in cancer therapy, including their interactions with cancer cells and the tumor microenvironment.
  5. Biocompatibility and Toxicity Assessment:
    Research evaluating the biocompatibility and potential toxicity of nanomaterials to ensure their safety in clinical applications.
  6. Emerging Nanotechnologies:
    Exploration of cutting-edge technologies, such as bioengineered nanoparticles and smart delivery systems, that represent the forefront of cancer nanotechnology.
Recent publications in "Cancer Nanotechnology" reveal several trending and emerging themes that reflect the dynamic nature of research in this field. These themes highlight innovative approaches and technologies that are gaining traction among researchers.
  1. Combination Therapies:
    An increasing number of studies are exploring combination therapies that incorporate nanoparticles with other treatment modalities, such as chemotherapy, immunotherapy, and radiation therapy, to enhance overall treatment efficacy.
  2. Smart Nanocarriers:
    Research on intelligent nanocarriers that respond to specific stimuli (e.g., pH, temperature, or light) for controlled drug release is gaining momentum, allowing for more precise and effective cancer treatment.
  3. Extracellular Vesicles and Biomimetic Nanoparticles:
    Emerging interest in using extracellular vesicles and biomimetic nanoparticles for drug delivery, leveraging their natural targeting abilities and biocompatibility to improve therapeutic outcomes.
  4. Nanotechnology in Immunotherapy:
    A notable trend in utilizing nanoparticles to enhance cancer immunotherapy, including the delivery of immune checkpoint inhibitors and other immunomodulatory agents, is becoming increasingly prevalent.
  5. Nanoparticle-mediated Gene Therapy:
    Growing research focus on the development of nanoparticle-based systems for the delivery of RNA and DNA therapeutics, such as siRNA and gene editing tools, to target cancer cells at the genetic level.
  6. Regenerative Nanotechnology:
    Investigation into the role of nanoparticles in promoting tissue regeneration and repair in the context of cancer therapy is emerging as a novel area of research.

Declining or Waning

While the journal continues to thrive in many areas, certain themes have shown signs of declining interest or publication frequency over recent years. This section highlights those waning scopes, reflecting shifts in research priorities within the field.
  1. Conventional Chemotherapy Alone:
    There is a noticeable decrease in studies focusing solely on conventional chemotherapy without the incorporation of novel nanotechnology approaches, indicating a shift towards combination therapies involving nanoparticles.
  2. Single Modality Treatments:
    Research centered on single modality treatments, such as traditional drug delivery methods without the use of nanocarriers, is becoming less common as the field increasingly favors multimodal strategies that combine various therapeutic approaches.
  3. Basic Nanoparticle Characterization:
    While fundamental studies on nanoparticle characterization were once prevalent, the focus has shifted towards applications and therapeutic outcomes, leading to fewer publications solely dedicated to characterization without a direct link to cancer therapy.
  4. Non-targeted Nanoparticle Applications:
    There is a declining emphasis on non-targeted applications of nanoparticles in cancer therapy, as more researchers pursue targeted delivery systems that enhance therapeutic efficacy and reduce off-target effects.

Similar Journals

ACS Biomaterials Science & Engineering

Fostering Innovation Through Rigorous Research and Collaboration
Publisher: AMER CHEMICAL SOCISSN: 2373-9878Frequency: 12 issues/year

ACS Biomaterials Science & Engineering, published by the American Chemical Society, serves as a premier platform for the latest advancements and research in the fields of biomaterials and biomedical engineering. With an impressive impact factor and a strong reputation reflected in its ranking—Q2 in Biomaterials and Q1 in Biomedical Engineering—the journal attracts a diverse and engaged readership. Since its inception in 2015, it has aimed to foster innovation by publishing high-quality research articles, reviews, and perspectives on the synthesis, characterization, and application of biomaterials. Researchers and professionals benefit from the journal's rigorous peer-review process and its focus on translational science, making it essential for those looking to stay at the forefront of biomaterials research. Located in Washington, DC, USA, the journal plays a pivotal role in connecting academic and industrial sectors, ultimately driving advancements that impact biomedicine and related fields.

Theranostics

Innovative Insights for Enhanced Patient Care.
Publisher: IVYSPRING INT PUBLISSN: 1838-7640Frequency: 1 issue/year

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.

MOLECULES

Connecting Ideas, Catalyzing Discoveries in Chemistry
Publisher: MDPIISSN: Frequency: 24 issues/year

MOLECULES, published by MDPI, stands as a prominent open-access journal dedicated to the field of chemistry, with an exceptional reputation in various sub-disciplines. Since its inception in 1997, this journal has committed itself to the dissemination of innovative research, spanning topics in Analytical Chemistry, Organic Chemistry, Pharmaceutical Science, and Drug Discovery. With impressive rankings across Scopus categories—including a coveted Q1 designation in both Analytical Chemistry and Pharmaceutical Science—MOLECULES is recognized as a vital resource for researchers, professionals, and students aiming to stay at the forefront of scientific development. The journal’s data reflect its wide-ranging influence, holding high percentiles in multiple chemistry categories, thereby ensuring that its articles reach a significant audience. As an open-access journal, it provides unparalleled access to its content, available freely and globally, which promotes further advancement and collaboration within the scientific community. Its ongoing commitment to high-quality research from 1996 to 2024 reinforces its status as a leader in the academic publishing landscape.

BME Frontiers

Empowering Research to Transform Healthcare
Publisher: AMER ASSOC ADVANCEMENT SCIENCEISSN: Frequency: 1 issue/year

BME Frontiers, published by the American Association for the Advancement of Science, is an innovative open-access journal dedicated to the burgeoning field of Biomedical Engineering. Since its establishment in 2020, this journal has aimed to bridge the gap between cutting-edge research and practical application, promoting advancements in biomedical technologies, medical devices, and healthcare solutions. Boasting impressive rankings within Scopus—64th among 398 in Medicine (miscellaneous) and 81st among 303 in Biomedical Engineering—BME Frontiers stands out as a significant contributor to scholarly communication, offering rich insights for researchers, professionals, and students alike. With consistent publication projected through 2024, the journal serves as an essential platform for disseminating high-quality research that can drive innovation and inspire new approaches in the healthcare sector.

Journal of Reports in Pharmaceutical Sciences

Unveiling the Future of Biopharmaceutical Technologies.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

International Journal of Nanomedicine

Transforming research into revolutionary healthcare solutions.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-2013Frequency: 1 issue/year

International Journal of Nanomedicine, published by DOVE MEDICAL PRESS LTD, is a leading open access journal dedicated to advancing the field of nanomedicine and its applications in healthcare. Since its establishment in 2006, the journal has grown significantly, now encompassing a wide array of topics including bioengineering, biomaterials, biophysics, drug discovery, and pharmaceutical sciences, and is recognized in Q1 quartiles across major categories like *Nanoscience and Nanotechnology* and *Organic Chemistry*. The journal boasts an impressive standing within the Scopus rankings, with high percentiles across various related fields, making it an invaluable resource for researchers, professionals, and students seeking to stay informed on the latest innovations and developments in nanomedicine. With its commitment to fostering an accessible and collaborative academic environment, the International Journal of Nanomedicine serves as a vital platform for disseminating transformative research that impacts scientific practice and healthcare outcomes globally.

Biomaterials Science

Pioneering advancements in biomaterials for a healthier world.
Publisher: ROYAL SOC CHEMISTRYISSN: 2047-4830Frequency: 24 issues/year

Biomaterials Science is a premier journal published by the Royal Society of Chemistry that serves as a leading platform for researchers and professionals in the fields of Biomedical Engineering and Materials Science. With an impressive impact factor bolstered by its Q1 quartile ranking in both disciplines, this journal has positioned itself at the forefront of cutting-edge research, showcasing innovative materials and applications that drive advancements in healthcare and technology. Since its inception in 2013, Biomaterials Science has been committed to disseminating high-quality, peer-reviewed articles that promote scientific knowledge and collaboration among academia and industry. With a global readership and a focus on open access, researchers are encouraged to share their findings to facilitate the development of transformative biomaterials and their applications. Join a vibrant community of scholars as we explore the future of biomaterials through this esteemed publication, enhancing both scientific inquiry and practical application.

Nanomedicine Journal

Transforming Healthcare with Nanoscience Discoveries.
Publisher: MASHHAD UNIV MED SCIENCESISSN: 2322-3049Frequency: 4 issues/year

Nanomedicine Journal, published by Mashhad University of Medical Sciences, serves as a vital platform for research and developments in the dynamic field of nanotechnology applied to medicine. With an ISSN of 2322-3049 and an E-ISSN of 2322-5904, this Open Access journal, operational since 2013, makes cutting-edge research freely accessible to encourage collaborative efforts in this rapidly evolving domain. The journal navigates various areas, including bioengineering, biomedical engineering, materials science, and pharmacology, holding prestigious rankings in categories relevant to these fields. The 2023 Scopus Rankings reveal its significant standing within the scientific community, particularly with a 76th percentile in general medicine. By bridging the gap between laboratory technologies and clinical applications, the Nanomedicine Journal aims to empower researchers, professionals, and students alike to contribute to the innovative landscape of nanomedicine. With a convergence period extending from 2019 to 2024 and an established reputation, this journal is essential for those pursuing advancements in therapeutic solutions and diagnostics through nanotechnology.

Biomaterials Research

Elevating the standards of biomaterials research.
Publisher: AMER ASSOC ADVANCEMENT SCIENCEISSN: 1226-4601Frequency: 1 issue/year

Biomaterials Research, published by the American Association for the Advancement of Science, is a prominent open access journal established in 2014, dedicated to advancing the field of biomaterials. Based in the United Kingdom, this journal has swiftly become an essential platform for researchers and practitioners, offering groundbreaking insights in biomaterials, biomedical engineering, ceramics and composites, and miscellaneous medical fields. With its impressive Q1 ranking across multiple relevant categories in 2023 and its strong Scopus rankings, including a remarkable 90th percentile in the medicine category, Biomaterials Research showcases high-quality, peer-reviewed research designed to address both practical and theoretical challenges in biomaterials science. As an open access journal, it promotes wider dissemination and accessibility of research findings, crucial for fostering innovation and collaboration within the scientific community. Researchers, professionals, and students alike are encouraged to contribute, read, and engage with the latest developments in this dynamic field.

Current Cancer Therapy Reviews

Elevating cancer research for a healthier future.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-3947Frequency: 2 issues/year

Current Cancer Therapy Reviews, an esteemed journal published by Bentham Science Publishers Ltd, serves as a critical resource in the fields of cancer research, molecular medicine, and oncology. With an ISSN of 1573-3947 and an E-ISSN of 1875-6301, this journal provides a platform for the rapid dissemination of reviews that articulate the latest advancements and therapeutic strategies in cancer treatment. Although it currently holds a Q4 classification in its respective categories, the journal's commitment to quality scholarship is evident in its engagement with an expansive range of topics impacting cancer care. Operating from the United Arab Emirates since its inception in 2006, it is an essential tool for researchers, clinicians, and students aiming to stay abreast of the evolving landscape of cancer therapy. The journal emphasizes open access to knowledge, fostering a collaborative environment for innovative research. For those looking to deepen their understanding of contemporary cancer therapies, Current Cancer Therapy Reviews is a valuable addition to their academic resources.